In medical news:

The U.S. Food and Drug Administration yesterday requested that Endo Pharmaceuticals remove its opioid pain medication, reformulated Opana ER (oxymorphone hydrochloride), from the market. The agency stated that it is seeking removal based on “its concern that the benefits of the drug may no longer outweigh its risks.” This is the first time the agency has taken steps to remove a currently marketed opioid pain medication from sale due to the public health consequences of abuse.

Read the full announcement here.

Leave a Comment

Your email address will not be published.